TICKERNERD
Menu
KRROKRROHealthcare · Biotechnology

KRRO Stock Forecast: Korro Bio, Inc. Price Predictions for 2026-2027

Last close, 10 Aug 2026
$13

The 11 Wall Street analysts covering Korro Bio, Inc. hold a median 12-month price target of $22 — +59.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 10 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$196.1M
Ticker Nerd rank
26 / 100
Median analyst target
$22
Analysts covering
11
Ticker Nerd rank

KRRO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Korro Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Aug 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Size
68
Growth
43
Issuance
42
Momentum
34
Revisions
30
Quality
24
Value
23
Volatility
4

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (4): The share price moves around a lot.

Wall Street

KRRO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KRRO, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says11 analysts
10 Buy1 Hold0 Sell
Low $10Median $22High $30

The green dot is the last close — the median target sits +59.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 May 2026HC Wainwright & Co.MaintainsBuy$20 → $15
18 May 2026CitigroupInitiatesBuy$21
13 Mar 2026Cantor FitzgeraldMaintainsOverweight—
13 Mar 2026Raymond JamesUpgradeOutperform—
19 Feb 2026Clear StreetUpgradeBuy—
17 Feb 2026William BlairUpgradeOutperform—
29 Jan 2026Chardan CapitalUpgradeBuy—
29 Jan 2026HC Wainwright & Co.UpgradeBuy—
29 Jan 2026Piper SandlerUpgradeOverweight—
28 Jan 2026Cantor FitzgeraldUpgradeOverweight—
28 Jan 2026OppenheimerUpgradeOutperform—
14 Nov 2025Jones TradingDowngradeHold—
13 Nov 2025Cantor FitzgeraldDowngradeNeutral—
13 Nov 2025Chardan CapitalDowngradeNeutral—
13 Nov 2025HC Wainwright & Co.DowngradeNeutral—
13 Nov 2025RBC CapitalDowngradeSector Perform—
13 Nov 2025William BlairDowngradeMarket Perform—
31 Oct 2025Clear StreetInitiatesBuy—
13 Aug 2025Chardan CapitalMaintainsBuy—
13 Aug 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KRRO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

KRRO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
2
Fundamentals

Korro Bio, Inc. (KRRO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.1×

Cheaper than 82% of US stocks

Price / sales
82.3×

Cheaper than 4% of US stocks

Price / book
1.9×

Cheaper than 48% of US stocks

EV / EBITDA
−1.7×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−3228.3%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−97.7%

Higher than 13% of US stocks

Return on assets
−28.0%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KRRO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KRROKorro Bio, Inc.$196.1M
26
CNXUConexeu Sciences, Inc.$194.5M
3
IMUXImmunic, Inc.$192.1M
25
IVVDInvivyd, Inc.$198.3M
29
PLXProtalix Biotherapeutics, Inc.$199.8M
74
ARCTArcturus Therapeutics Holdings, Inc.$200.3M
56
VYGRVoyager Therapeutics, Inc.$188.9M
74

The rank is the raw material. Whether the rules would actually own Korro Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KRRO news & analysis

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Zacks Investment Research · 10 Aug 2026positive

Zacks Investment Research upgraded Korro Bio, Inc. (KRRO) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects. The rating action may influence near-term stock movement.

Why it matters — A KRRO watcher would care because the upgrade signals improved confidence in the company's earnings outlook and could affect the stock's near-term performance.

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 6 Aug 2026positive

Korro Bio reported its second quarter 2026 financial results and provided a corporate update. The company announced that its lead candidate KRRO-121 for hyperammonemia is on track for a first-in-human trial in the second half of 2026, received Orphan Drug Designation from the EMA for KRRO-121, nominated KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency, and ended the quarter with $137.9 million in cash, with a runway into the second half of 2028.

Why it matters — KRRO watchers would care because the update confirms clinical program progress, a new regulatory milestone, a second development candidate, and a cash runway extending into 2028.

FAQ

Frequently asked questions about KRRO stock

What is the KRRO stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Korro Bio, Inc. have a median 12-month price target of $22, with estimates ranging from $10 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KRRO stock a buy right now?

Of the 11 analysts covering Korro Bio, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Korro Bio, Inc. 26 out of 100 across roughly 4,600 US stocks as at 10 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KRRO?

As at 10 Aug 2026, Korro Bio, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

Will KRRO stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +59.4% from the last close, and Ticker Nerd's factor model ranks Korro Bio, Inc. 26 out of 100 as at 10 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KRRO stock forecast for 2030?

No analyst covering Korro Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $30 over the next 12 months.

What does Korro Bio, Inc. do?

Korro Bio Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts.

What is the latest news on KRRO?

The most recent item we track (Zacks Investment Research, 10 Aug 2026): "All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy". Zacks Investment Research upgraded Korro Bio, Inc. (KRRO) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects. The rating action may influence near-term stock movement.

Company

About Korro Bio, Inc.

Korro Bio Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company develops genetic medicines that utilize RNA editing to treat rare and highly prevalent diseases. Its proprietary Oligonucleotide Promoted Editing of RNA (OPERA) platform recruits endogenous enzymes like ADAR to enable precise, transient single-base edits on RNA transcripts, repairing disease-causing mutations or modulating protein function without altering DNA. This oligonucleotide-based approach leverages established delivery methods such as GalNAc conjugation for liver targeting. Korro Bio Inc.'s lead program, KRRO-110, targets Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder causing lung and liver damage, and is in Phase 1/2 clinical trials. The company is also advancing KRRO-121 for hyperammonemia associated with urea cycle disorders and hepatic encephalopathy, along with programs in cardiometabolic diseases through a collaboration with Novo Nordisk, and explorations in Parkinson's disease and amyotrophic lateral sclerosis. Korro Bio Inc. focuses on liver-targeted and other tissue-specific therapies, positioning RNA editing as a tunable alternative in genetic medicine.

CEO Dr. Ram Aiyar MBA, Ph.D. · 57 employees · United States · https://www.korrobio.com